SEC
SlamSEC
Search
Browse
Earnings
Evolus, Inc. — SlamSEC
Evolus, Inc.
Nasdaq:
EOLS
Pharmaceutical Preparations
·
NEWPORT BEACH, CA
Overview
All Filings
Sum Fin
Credit
Insiders
Governance
Overview
All Filings
Sum Fin
Credit
Insiders
Governance
Summary Financials
Revenue
$202.1M
+36.0% YoY
FY 2025
Adj. EBITDA
-$44.1M
-21.8% margin
FY 2025
Net Income
-$61.7M
-30.5% margin
FY 2025
EPS (Diluted)
-$1.08
FY 2025
Stock Price
$5.35
-3.4%
2026-03-09
52W Range
$4.09 – $13.66
P/E Ratio
-5.0x
Market Cap
$348.1M
Cash
$87.0M
FY 2025
Total Debt
$138.7M
FY 2019
Net Debt
$51.7M
FY 2019
Enterprise Value
$399.8M
Debt / EBITDA
-1.2x
FY 2025
EV / EBITDA
-9.1x
Employees
—
CFO
Mitchell Tatjana